AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
A prominent player of Healthcare Sector Hemogenyx Pharmaceuticals PLC has announced the successful development of a clinical-grade assay designed to measure FLT3 protein levels in acute myeloid leukaemia (AML) cells. This assay is a crucial component for selecting patients for the company's upcoming phase I clinical trials of its HEMO-CAR-T treatment.
Significance of the New Assay
The FLT3 assay is pivotal for the accurate identification of patients who are eligible for the phase I clinical trials, which are set to commence shortly at MD Anderson Cancer Center. Following the initial phase at MD Anderson, the trials will expand to include the University of Pennsylvania Medical Center. The successful development of this assay underscores Hemogenyx Pharmaceuticals' commitment to advancing its therapeutic solutions for cancer and viral diseases.
Implications for Upcoming Clinical Trials
The introduction of this assay represents a significant advancement for Hemogenyx Pharmaceuticals (LSE: HEMO) as it prepares to initiate its phase I trials. The assay's role in ensuring precise patient selection is expected to play a key part in the overall success of the trials. Accurate patient identification is essential for evaluating the effectiveness of the HEMO-CAR-T treatment, which aims to offer new treatment options for those battling AML.
Hemogenyx Pharmaceuticals continues to focus on developing innovative therapies in the biopharmaceutical sector, with this milestone marking an important step forward in the progression of its clinical development programs.
